Instil Bio, Inc. · NASDAQ:TIL
Instil Bio — Investor Presentation (September 2024)
12 slides from Instil Bio's investor presentation, Sep 16, 2024
Slide 1: Instil Bio Corporate Presentation September 2024
Instil Bio Corporate Presentation September 2024 Nasdaq: TIL │ www.instilbio.com
Slide 2: Forward Looking Statements
Forward Looking Statements 2 This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates,” “believes,” “expects,” "expected,” “exploring,” “future,” “intends,” “may,” “plans,” “potential,” “projects,” an
Slide 3: Global SYN-2510/IMM2510 Development Strategy
Global SYN-2510/IMM2510 Development Strategy 3 2025 2026 20272H 2024 China (ImmuneOnco) US (Instil) Global (both) Ph1b 2L+ monotherapy Ph3 1L NSCLC** NSCLC Indication Expansion Ph1b 2L+ monotx. Renal Cell Carcinoma Hepatocellular Carc. Other Solid Tumors SYN-27M Combo TNBC Ph3 1L TNBC** Ph2 2L+ mono
Slide 4: Key features of SYN-2510, bispecific PD-L1xVEGF antibody
Key features of SYN-2510, bispecific PD-L1xVEGF antibody 4 Differentiated design • PD-L1 targeting • VEGF trap • ADCC-enhanced Collaboration with ImmuneOnco (HKEX:1541) • In China, opportunity to leverage proof-of- concept data generation and accelerate clinical development Combination of validated
Slide 5: Key Competitor Landscape
5 Key Competitor Landscape Anti-PD-L1 VHH Silenced Fc (LALA) Anti-VEGF-A Anti-VEGF-A Anti-PD-1 Anti-PD-L1 VEGF Trap ADCC- enhanced SYN-2510 BNT327 (Biotheus / BioNTech) Ivonescimab (Akeso / Summit) VEGF binding VEGF-A, VEGF-B, PLGF VEGF-A VEGF-A PD-1 or PD-L1 PD-L1 PD-L1 PD-1 ADCC Enhanced ADCC None
Slide 6: PD-1xVEGF bispecific ivonescimab has demonstrated superiority vs Keytruda
PD-1xVEGF bispecific ivonescimab has demonstrated superiority vs Keytruda® 6 • Ivonescimab (PD-1xVEGF bispecific) monotherapy demonstrated stat. sig. improvement in PFS vs. Keytruda® monotherapy in 1L NSCLC • First randomized phase 3 trial reported of a regimen outperforming standard-of- care Keytru
Slide 7: PD-L1xVEGF bispecific BNT327 has demonstrated clinical activity in multiple solid tumors
PD-L1xVEGF bispecific BNT327 has demonstrated clinical activity in multiple solid tumors 7 • BNT327 has demonstrated “Strong single compound activity, and high ORRs observed in combination with CTx in various indications” Source: BioNTech Q2 2024 earnings presentation
Slide 8: SYN-2510 achieved responses in NSCLC patients with prior PD-1 inhibitor in Phase 1a
SYN-2510 achieved responses in NSCLC patients with prior PD-1 inhibitor in Phase 1a 8 Thymus adenosqumous carcinomaSquamous NSCLC Squamous NSCLC SYN-2510 completed dose escalation up to 20 mg/kg Q2W with a manageable safety profile and no observed dose-limiting toxicities (DLT) Source: ImmuneOnco in
Slide 9: SYN-2510 achieved multiple PR and SD in dose escalation
SYN-2510 achieved multiple PR and SD in dose escalation 9 Source: ImmuneOnco interim results for the six months ended June 30, 2024
Slide 10: ImmuneOnco collaboration provides opportunity to accelerate global clinical development of SYN-2510
ImmuneOnco collaboration provides opportunity to accelerate global clinical development of SYN-2510 • Collaboration with ImmuneOnco (HKEX:1541), a Hong Kong-listed biotech developing SYN-2510/IMM2510 in China • Potential opportunities to utilize ImmuneOnco’s clinical dataset: ▪ Proof-of-concept in t
Slide 11: Recent (Q2'24 Earnings PR)
Recent Corporate Update (Q2’24 Earnings PR) 11
Slide 12: Thank you
Thank you Investor Relations (972) 499-3350 investorrelations@instilbio.com